Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01662986 · ClinicalTrials.gov registry record · Phase 4

Investigate the Impact of Early Treatment Initiation With Tiotropium in Patients Recovering From Hospitalization for an Acute COPD Exacerbation 2

A Phase 4 study of Pulmonary Disease, Chronic Obstructive, sponsored by Boehringer Ingelheim.

Completed
Registry status
Phase 4
Development phase
79
Enrollment target
20
Study locations

NCT01662986 is a Phase 4 study of Pulmonary Disease, Chronic Obstructive that has completed, run by Boehringer Ingelheim. The registered enrollment target is 79 participants, below the 1,043-participant average among 74 other Pulmonary Disease, Chronic Obstructive trials with a reported enrollment target (92% lower). The trial reports 20 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01662986, a Phase 4 study of Pulmonary Disease, Chronic Obstructive, has completed, sponsored by Boehringer Ingelheim.

COMPLETED
Registry status
Phase 4
Development phase
79 participants
Enrollment target
20
Study locations

Study Summary

A randomized, placebo-controlled, double-blind, parallel group, multi-center study to assess the safety and efficacy of tiotropium bromide (18 µg) delivered via the HandiHaler® in Chronic Obstructive Pulmonary Disease (COPD) subjects recovering from hospitalization for an acute exacerbation (Hospital Discharge Study 2)

Conditions Studied

Pulmonary Disease, Chronic Obstructive

Interventions

  • DRUG Placebo
  • DRUG tiotropium bromide

Study Locations (20)

Florida

  • 205.478.00200 Boehringer Ingelheim Investigational Site - Jacksonville
  • 205.478.00212 Boehringer Ingelheim Investigational Site - Jacksonville
  • 205.478.00265 Boehringer Ingelheim Investigational Site - Kissimmee
  • 205.478.00246 Boehringer Ingelheim Investigational Site - Lehigh Acres
  • 205.478.00248 Boehringer Ingelheim Investigational Site - Miami
  • 205.478.00215 Boehringer Ingelheim Investigational Site - Orlando
  • 205.478.00261 Boehringer Ingelheim Investigational Site - St. Petersburg
  • 205.478.00233 Boehringer Ingelheim Investigational Site - Vero Beach

California

  • 205.478.00241 Boehringer Ingelheim Investigational Site - Loma Linda
  • 205.478.00240 Boehringer Ingelheim Investigational Site - Long Beach
  • 205.478.00237 Boehringer Ingelheim Investigational Site - Torrance

Connecticut

  • 205.478.00209 Boehringer Ingelheim Investigational Site - Danbury
  • 205.478.00250 Boehringer Ingelheim Investigational Site - Glastonbury
  • 205.478.00229 Boehringer Ingelheim Investigational Site - Hartford

Arizona

  • 205.478.00208 Boehringer Ingelheim Investigational Site - Flagstaff
  • 205.478.00260 Boehringer Ingelheim Investigational Site - Glendale

Georgia

  • 205.478.00236 Boehringer Ingelheim Investigational Site - Austell
  • 205.478.00205 Boehringer Ingelheim Investigational Site - Lawrenceville

Alabama

  • 205.478.00243 Boehringer Ingelheim Investigational Site - Montgomery

Colorado

  • 205.478.00231 Boehringer Ingelheim Investigational Site - Denver

Trial Details

FieldValue
Enrollment Target 79 participants
Start Date 2012-08-01
Est. Completion 2014-04-01
Phase Phase 4

Sponsor

Boehringer Ingelheim

515 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01662986

The ClinicalTrials.gov registry entry for NCT01662986 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 79 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,043-participant average among 74 other Pulmonary Disease, Chronic Obstructive trials with a reported enrollment target (92% lower). The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Pulmonary Disease, Chronic Obstructive appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT01662986 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Florida, California, Connecticut.

Frequently Asked Questions

What is clinical trial NCT01662986 about?

NCT01662986 is a clinical study titled "Investigate the Impact of Early Treatment Initiation With Tiotropium in Patients Recovering From Hospitalization for an Acute COPD Exacerbation 2". A randomized, placebo-controlled, double-blind, parallel group, multi-center study to assess the safety and efficacy of tiotropium bromide (18 µg) delivered via the HandiHaler® in Chronic Obstructive Pulmonary Disease (COPD) subjects recovering from hospitalization for an acute exacerbation (Hospita...

What is the current status of trial NCT01662986?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 79 participants. The study started on 2012-08-01. Estimated completion is 2014-04-01.

What conditions does trial NCT01662986 study?

This clinical trial studies the following conditions: Pulmonary Disease, Chronic Obstructive.

What interventions are being tested in trial NCT01662986?

The interventions under investigation include: Placebo (DRUG), tiotropium bromide (DRUG).

Who is sponsoring clinical trial NCT01662986?

This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01662986 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Pulmonary Disease, Chronic Obstructive

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Pulmonary Disease, Chronic Obstructive

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.